Carla Rognoni

Carla Rognoni is Researcher of Health Economics & HTA within the Government, Health and Not for Profit Knowledge Group of SDA Bocconi School of Management.

She started the collaboration with CERGAS Bocconi in 2008. At SDA Bocconi Carla coordinates and works actively on different research projects in health economics involving either pharmacological treatments or medical devices with Abbvie, BD, Boston Scientific, Johnson & Johnson, Novartis, Vifor Pharma and many others. She frequently develops project proposals and manages also ethical aspects by interacting with the Bocconi Ethics Committee.

Her research activities focus on a variety of topics related to health technology assessment (HTA) in both public health and clinical medicine: economic evaluations, evaluation of quality of life, cost-effectiveness and budget impact analyses, decision modelling (including Markov processes) and preparation of deliverables for market access purposes.

She published on health economic topics more than 130 papers/abstracts (more than 60 indexed in Pubmed, H-index 20) and few book chapters. Her works have been published in Value in Health, Journal of Comparative Effectiveness Research, Clinical Therapeutics, Clinical Drug Investigation, Lancet Oncology, Scientifi Reports, Medical Decision Making and many other Journals. Carla serves as reviewer for various international Journals. She is a member of Italian Health Economics Association (AIES) and International Society for Pharmacoeconomics and Outcome Research (ISPOR). She was also appointed from 2016 to 2019 as a member (expert in pharmacoeconomics) of the Drugs Committee at IRCCS Policlinico San Matteo in Pavia, Italy.

Carla earned a MSc in Computer Science and Engineering from the University of Pavia and a PhD in Bioengineering and Bioinformatics (cum laude), awarded based on her research on the topics of decision analysis (cost-effectiveness analysis, cost-utility analysis and modelling of Markov processes) in the prevention of sudden deaths caused by long QT-syndrome.

Teaching domains

• Health Technology Assessment
• Quality of Life
• Markov Models
• Meta-Analysis
• Systematic Reviews

Latest publications

FEDERICI C. B., ROGNONI C., COSTA F., ARMENI P., CROVATO E., BELLUCCI S. Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma Clinical Therapeutics, 1 October, 2022

ROGNONI C., BARCELLONA M. R., BARGELLINI I., BAVETTA M. G., BELLÒ M., BRUNETTO M., CARUCCI P., CIONI R., CROCETTI L., D’AMATO F., D’AMICO M., DEAGOSTINI S., DEANDREIS D., DE SIMONE P., DORIGUZZI A., FINESSI M., FONIO P., GRIMALDI S., IALUNA S., LAGATTUTA F., MASI G., MORECI A., SCALISI D., VIRDONE R., TARRICONE R. Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma Frontiers in Oncology, 2022, vol.12, pp.1-10

FORNARO G., FEDERICI C. B., ROGNONI C., CIANI O. Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies Value in Health, 2021, vol.24, no. 7, pp.1045-1058

TORBICA A., ROGNONI C., TARRICONE R. Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine International Journal of Environmental Research and Public Health, 2021, vol.18, no. 9, pp.4916

ROGNONI C., BERTOLANI A., JOMMI C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects Clinical Drug Investigation, 2021, vol.41, no. 4, pp.303-319

ROGNONI C., LUGLI M., MALETI O., TARRICONE R. Clinical Guidelines Vs. Current Clinical Practice for the Management of Deep Vein Thrombosis: Where do We Stand? Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, vol.9, no. 5, pp.1334-1344